

# Recombinant Human Insulin-like Growth Factor-Binding Protein 3

Catalog No: #AP60064


Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)

Package Size: #AP60064-1 5ug #AP60064-2 100ug #AP60064-3 500ug

## Description

Product Name	Recombinant Human Insulin-like Growth Factor-Binding Protein 3
Host Species	Escherichia coli.
Purification	> 98 % by SDS-PAGE and HPLC analyses.
Other Names	Growth-hormone-dependant Binding Protein, IBP-3, IGF-binding protein 3
Calculated MW	Approximately 28.8 kDa, a single non-glycosylated polypeptide chain containing 264 amino acids.
Target Sequence	GASSAGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAGNA SESEEDRSAG SVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGfYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK
Formulation	Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

## Images



## Background

Insulin-like Growth Factor-Binding Protein 3 (IGF-BP3) belongs to the IGFBP family, which are all cysteine-rich proteins with conserved cysteine and have an IGFBP domain and a thyroglobulin type-I domain. Mature human IGF-BP3 contains 264 a.a. with three potential N-linked and two potential O-linked glycosylation sites. It is expressed by most tissues and has higher levels during extrauterine life and peak during puberty. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. The protein forms a ternary complex with IGF-I or II and acid-labile subunit. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Decreased plasma levels of IGF-BP3 often happen during the progression of prostate cancer from benign to metastatic disease.

---

Note: This product is for in vitro research use only and is not intended for use in humans or animals.